<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Saudi J Gastroenterol</journal-id>
      <journal-id journal-id-type="publisher-id">SJG</journal-id>
      <journal-title-group>
        <journal-title>Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1319-3767</issn>
      <issn pub-type="epub">1998-4049</issn>
      <publisher>
        <publisher-name>Medknow Publications</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21372355</article-id>
      <article-id pub-id-type="pmc">3099063</article-id>
      <article-id pub-id-type="publisher-id">SJG-17-145</article-id>
      <article-id pub-id-type="doi">10.4103/1319-3767.77248</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A New Candidate as a Hemostatic Agent for Difficult Situations During Variceal Bleeding: Ankaferd Blood Stopper</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ozaslan</surname>
            <given-names>Ersan</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Purnak</surname>
            <given-names>Tugrul</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yildiz</surname>
            <given-names>Ayla</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Haznedaroglu</surname>
            <given-names>Ibrahim C.</given-names>
          </name>
          <xref ref-type="aff" rid="AF0002">1</xref>
        </contrib>
      </contrib-group>
      <aff id="AF0001">Department of Gastroenterology, Numune Education and Research Hospital, Ankara, Turkey</aff>
      <aff id="AF0002"><label>1</label>Department of Hematology, Hacettepe Faculty of Medicine, Ankara, Turkey</aff>
      <author-notes>
        <corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Ersan Ozaslan, Cukurambar Mah. 40. Cad. 5/13, Cankaya, Ankara, Turkey. E-mail: <email xlink:href="er72@hotmail.com">er72@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Mar-Apr</season>
        <year>2011</year>
      </pub-date>
      <volume>17</volume>
      <issue>2</issue>
      <fpage>145</fpage>
      <lpage>148</lpage>
      <history>
        <date date-type="received">
          <day>06</day>
          <month>1</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>8</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Saudi Journal of Gastroenterology</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Variceal bleeding is the most challenging emergent situation among the causes of upper gastrointestinal bleeding. Despite substantial improvement, a need remains for therapeutic armamentarium of such cases, which is easy, effective and without side-effect. Ankaferd blood stopper (ABS) is a standardized herbal extract acting as a hemostatic agent on the bleeding or injured areas. In this observational study, a total of four patients with variceal bleeding were treated with endoscopic ABS application. The lesions were bleeding gastric varices (n:3) and bleeding duodenal varix (n:1). ABS was selected as a bridge to definitive therapies due to unavailability or inappropriateness of bleeding lesions to conventional measures. ABS was instilled or flushed onto the bleeding areas by sclerotherotherapy needle or heater probe catheter. Periprocedural control of the bleeding was achieved in all instances. Thereafter, on an elective basis, two patients with gastric varices underwent cyanoacrylate injection, while third underwent Transjugular intrahepatic portosystemic shunt and embolization. The patient with duodenal varix refused further therapy, after a few hours after admission and was discharged. He again presented the same day with rebleeding, but died before any attempt could be made to control his bleeding. ABS seems to be effective in cases of variceal bleeding as a bridge to therapy. Its major advantages are the ease of use and lack of side-effects.</p>
      </abstract>
      <kwd-group>
        <kwd>Ankaferd blood stopper</kwd>
        <kwd>duodenal varices</kwd>
        <kwd>endoscopy</kwd>
        <kwd>gastric varices</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Endoscopic variceal ligation and/or injection sclerotherapy are well-established measures of bleeding esophageal varices despite some failures and complications; hovewer, the management of gastric and ectopic varices is more challenging. Cyanoacrylate injection is currently recommended for endoscopic treatment of gastric variceal bleeding.[<xref ref-type="bibr" rid="CIT1">1</xref>] Transjugular intrahepatic portosystemic shunt (TIPS) is recommended for patients in whom bleeding recurs despite combined medical and endoscopic therapy. When the standard treatment methods are inefficient or unavailable, it is obvious that the simplier methods should be available until TIPS procedure can be performed in a well-equipped center. In addition to controversies about the technical details and potential adverse complications of cyanoacrylate, such as thromboembolism,[<xref ref-type="bibr" rid="CIT2">2</xref>] it is costly and largely unavailable in many centers. In Turkey, cyanoacrylate is not reimbursable, and even direct purchase by patients may result in delays to therapy in urgent settings.</p>
    <p>Ankaferd blood stopper (ABS) is a Turkish folkloric herbal extract obtained from five different plants, <italic>Thymus vulgaris</italic> (thyme), <italic>Glycyrrhiza glabra</italic> (licorice), <italic>Vitis vinifera</italic> (grape), <italic>Alpinia officinarum</italic> (lesser galangal) and <italic>Urtica dioica</italic> (stinging nettle). The use of topical ABS as a hemostatic agent has been approved by the Turkish Ministry of Health for the management of dermal, external postsurgical and postdental surgery bleedings.[<xref ref-type="bibr" rid="CIT3">3</xref>] The <italic>in vivo</italic> hemostatic effect of ABS was evaluated in rats pretreated with acetylsalicylic acid or enoxaparine as well as in a swine model.[<xref ref-type="bibr" rid="CIT4">4</xref><xref ref-type="bibr" rid="CIT5">5</xref>] Recently, a prospective, controlled clinical trial (phase III) of ABS in bleeding during tonsillectomy has been reported.[<xref ref-type="bibr" rid="CIT6">6</xref>] The successful usage of ABS has been described in various gastrointestinal (GI) scenarios as case reports, such as Dieulafoy lesion[<xref ref-type="bibr" rid="CIT7">7</xref>] and neoplastic GI bleeding.[<xref ref-type="bibr" rid="CIT8">8</xref>] Moreover, bleeding due to tooth-extraction in a cirrhotic patient with deficient hemostasis was controlled by ABS.[<xref ref-type="bibr" rid="CIT9">9</xref>]</p>
    <sec sec-type="cases" id="sec1-1">
      <title>CASE REPORTS</title>
      <p>This is an observational study of four patients presenting with variceal bleeding. ABS was used in five bleeding sessions (twice in one patient) as a primary hemostatic agent due to unavailabilities or difficulties of the conventional measures. We selected ABS as a hemostatic agent in gastric varices cases (patients 1-3) due to unavailability of cyanoacrylate and in patient 4 due to huge size of duodenal varices. Moreover, massive bleeding and hemodynamic instability of cases forced us to apply a more practical measure. Patients demographics, definition of bleeding and follow-up during and after endoscopic procedures were noted [Tables <xref ref-type="table" rid="T0001">1</xref> and <xref ref-type="table" rid="T0002">2</xref>].</p>
      <table-wrap id="T0001" position="float">
        <label>Table 1</label>
        <caption>
          <p>The characteristics of patients and initial bleeding</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="center" colspan="3" rowspan="1">Patient features<hr/></th>
              <th align="center" colspan="3" rowspan="1">Definition of bleeding<hr/></th>
            </tr>
            <tr>
              <th align="left" rowspan="1" colspan="1">Age/Sex</th>
              <th align="left" rowspan="1" colspan="1">Diagnosis</th>
              <th align="left" rowspan="1" colspan="1">Bleeding source</th>
              <th align="left" rowspan="1" colspan="1">Symptoms and signs</th>
              <th align="left" rowspan="1" colspan="1">Hb /Hct</th>
              <th align="left" rowspan="1" colspan="1">Transfusion<xref ref-type="table-fn" rid="T00F1">*</xref></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">40/F</td>
              <td align="left" rowspan="1" colspan="1">Cryptogenic cirrhosis</td>
              <td align="left" rowspan="1" colspan="1">Gastric varices (IGV-1, large, tortuous)</td>
              <td align="left" rowspan="1" colspan="1">Hematemesis Hypotension (80/50 mmHg) Tachycardia (135/min)</td>
              <td align="left" rowspan="1" colspan="1">6.9 gm/dL (19.2%)</td>
              <td align="left" rowspan="1" colspan="1">3 units whole blood</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">65/F</td>
              <td align="left" rowspan="1" colspan="1">Cryptogenic cirrhosis</td>
              <td align="left" rowspan="1" colspan="1">Gastric varices (IGV-1, large, tortuous)</td>
              <td align="left" rowspan="1" colspan="1">Hematemesis Hematochezia Hypotension (88/55 mmHg) Tachycardia (1115/min)</td>
              <td align="left" rowspan="1" colspan="1">8.1 gm/dL (24%)</td>
              <td align="left" rowspan="1" colspan="1">3 units whole blood</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">66/M</td>
              <td align="left" rowspan="1" colspan="1">Cryptogenic cirrhosis</td>
              <td align="left" rowspan="1" colspan="1">Gastric varices (with small esophageal varices, large, tortuous)</td>
              <td align="left" rowspan="1" colspan="1">Hematemesis Melena Hypotension (85/55 mmHg) Tachycardia (122/min)</td>
              <td align="left" rowspan="1" colspan="1">8.0 gm/dL (22%)</td>
              <td align="left" rowspan="1" colspan="1">2 units whole blood</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">48/M</td>
              <td align="left" rowspan="1" colspan="1">Alcoholic cirrhosis</td>
              <td align="left" rowspan="1" colspan="1">Duodenal varices (huge, tortuous)</td>
              <td align="left" rowspan="1" colspan="1">Hematemesis Melena Hypotension (95/60 mmHg) Tachycardia (111/min)</td>
              <td align="left" rowspan="1" colspan="1">8.8 gm/dL (26%)</td>
              <td align="left" rowspan="1" colspan="1">2 units RBC</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T00F1">
            <label>*</label>
            <p>Total number of transfusions performed before and during the endoscopy. IGV-1: isolated gastric varices</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="T0002" position="float">
        <label>Table 2</label>
        <caption>
          <p>The details of procedures and follow-up</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="center" colspan="3" rowspan="1">Endoscopic features<hr/></th>
              <th align="center" colspan="2" rowspan="1">Postendoscopic follow&#x2013;up<hr/></th>
            </tr>
            <tr>
              <th align="left" rowspan="1" colspan="1">No.</th>
              <th align="left" rowspan="1" colspan="1">Reason of ABS use</th>
              <th align="left" rowspan="1" colspan="1">Procedure/ the time of hemostasis achieved</th>
              <th align="left" rowspan="1" colspan="1">Early</th>
              <th align="left" rowspan="1" colspan="1">Late</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">1</td>
              <td align="left" rowspan="1" colspan="1">Massive bleeding Hemodynamic instability Unavailability of cyanoacrylate</td>
              <td align="left" rowspan="1" colspan="1">ABS (20 ml) 8<sup>th</sup> minute</td>
              <td align="left" rowspan="1" colspan="1">Elective cyanoacrylate injection on 3<sup>rd</sup> day</td>
              <td align="left" rowspan="1" colspan="1">Stable at 7<sup>th</sup> mo</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">2</td>
              <td align="left" rowspan="1" colspan="1">Massive bleeding Hemodynamic instability Unavailability of cyanoacrylate</td>
              <td align="left" rowspan="1" colspan="1">ABS (15 ml) 5<sup>th</sup> minute</td>
              <td align="left" rowspan="1" colspan="1">Elective cyanoacrylate injection on 3<sup>rd</sup> day, spurting during the procedure, restopped by ABS (25 ml)</td>
              <td align="left" rowspan="1" colspan="1">Stable at 5<sup>th</sup> mo</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">3</td>
              <td align="left" rowspan="1" colspan="1">Massive bleeding Hemodynamic instability Unavailability of cyanoacrylate</td>
              <td align="left" rowspan="1" colspan="1">ABS (15 ml) 5<sup>th</sup> minute</td>
              <td align="left" rowspan="1" colspan="1">No injection of cyanoacrylate Elective TIPS and embolization with coils at 7<sup>th</sup> day</td>
              <td align="left" rowspan="1" colspan="1">Stable at 3<sup>rd</sup> mo</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">4</td>
              <td align="left" rowspan="1" colspan="1">Recent bleeding Unavailability of cyanoacrylate</td>
              <td align="left" rowspan="1" colspan="1">ABS (7 ml) 3<sup>rd</sup> minute</td>
              <td align="left" rowspan="1" colspan="1">Voluntarily discharge from hospital after six hours of observation Exitus from rebleeding sixteen hours after the procedure</td>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>ABS: endoscopic topical use of Ankaferd blood stopper; GV: Gastric varices ; mo: Months</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>For all patients, written informed consent regarding the off-label use of ABS as a means of attaining hemostasis had been obtained from themselves or relatives. In all procedures, ABS was applied topically at varying doses [<xref ref-type="table" rid="T0002">Table 2</xref>]. Fujinon<sup>&#xAE;</sup>(EG450WR5, Fujionon Corporation, Saitama, Japan) diagnostic endoscopes were used for the topical application of ABS via sclerotherapy needle or heater probe catheter by the same senior endoscopist (E.O.). The vials of ABS&#xAE; (patent number 2007-0-114485 were provided by Ankaferd Drug Inc., Istanbul, Turkey (one vial of 100 ml).</p>
      <p>Periprocedural control of bleeding was attained in all instances and persisted for a few days except a fatal rebleeding after 16 hours in the patient with duodenal varix [<xref ref-type="table" rid="T0002">Table 2</xref>].</p>
      <p>Endoscopic diagnoses were massively bleeding gastric varices in patients 1 to 3 [Figures <xref ref-type="fig" rid="F0001">1</xref> and <xref ref-type="fig" rid="F0002">2</xref>]. They became hemodynamically unstable towards the end of the procedure. At that time, repeating the procedure via therapeutic endoscope with good suction capabilities or prokinetic agents to clear the visual field, Sangstaken-Blakemore tube or conservative measures were the options to bridge for a more definitive measure. We used 20 ml (for patient 1) and 15 ml (for patients 2 and 3) ABS solution that was sprayed in a random, untargeted fashion, with a heater probe catheter onto the bleeding areas beginning from the distal esophagus [<xref ref-type="fig" rid="F0001">Figure 1</xref>]. Thereafter, targeted application was tried as bleeding decreased. This produced greyish-yellow coagulum like a sludge throughout the stomach and bleeding stopped within minutes [<xref ref-type="fig" rid="F0002">Figure 2</xref>]. The cases were put on somatostatin and proper conservative therapy. In control endoscopy, patients 1 and 2 were made to undergo cyanoacrylate injection as a definitive therapy (1 ml Glubran<sup>&#xAE;</sup>(GEM, Viareggio, Italy) plus 1.6 ml Lipiodol<sup>&#xAE;</sup>(Guerbet Laboratories, Aulnay-sous-Bois, France). During the procedure on patient 2, massive bleeding occured after the second injection which decreased after further injections. However, massive hematemesis after 1 hour prompted us to perform the third endoscopy. ABS (25 ml) was reapplied and bleeding was stopped again. Patient 3 who had very large variceal columns, underwent a successful TIPSS and coil embolization at the seventh day of follow-up.</p>
      <fig id="F0001" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Case 2. Active bleeding (a) due to spurting gastric varix on retroflexion (b). ABS spraying via heater probe catheter in a random manner from distal esophagus (c), caused formation of ABS-induced plugs (arrows) and bleeding stopped (d)</p>
        </caption>
        <graphic xlink:href="SJG-17-145-g001"/>
      </fig>
      <fig id="F0002" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Case 2 (continued). Ankaferd Blood Stopper-induced coagulum are apparent on forward views at the proximal stomach (arrows) (a-b). Completely cleared stomach with gastric varix on the following day (c)</p>
        </caption>
        <graphic xlink:href="SJG-17-145-g002"/>
      </fig>
      <p>Patient 4 with alcoholic cirrhosis presented with relatively good hemodynamic features despite low hemoglobin level [<xref ref-type="table" rid="T0001">Table 1</xref>]. In upper endoscopy, moderate fresh bleeding and fissuring on a large varix was detected at the distal duodenum. ABS application induced hemostasis for 6 hours during admission, however, the patient subsequently discharged himself against medical advice.</p>
      <p>He came again the same night with re-bleeding, but died before any attempt could be made to stop the bleeding.</p>
    </sec>
    <sec sec-type="discussion" id="sec1-2">
      <title>DISCUSSION</title>
      <p>Although many effective approaches to endoscopic hemostasis have evolved in recent decades, each has some restrictions. The endoscopist&#x2019;s decision to use any one alone or in combination is determined largely by availability, personal preference and local expertise. Moreover, current endoscopic methods require identification of the bleeding focus. Excessive blood covering the examination field may cause diagnostic failure in 1.7 to 6.3% of non-variceal bleeding cases. This figure may be much higher in daily clinical practice especially with variceal bleeding, because many centers do not have therapeutic endoscopes and suitable aspiration devices while the endoscopist is usually forced to perform an early endoscopy. Our small case series showed that ABS may offer a useful adjunct in the therapeutic armamentarium of variceal bleeding cases due to the ease of application, non-toxicity and low cost. Neither any local adverse effect nor systemic toxicity was observed yet after the topical or even high-dose application of ABS.[<xref ref-type="bibr" rid="CIT4">4</xref><xref ref-type="bibr" rid="CIT5">5</xref><xref ref-type="bibr" rid="CIT10">10</xref>] However, intravariceal application of ABS should not be used due to its pro-coagulant action which may theoretically result in embolisation.</p>
      <p>The major argument to the hemostatic effect of ABS may be spontaneous cessation of GI bleeding under conservative therapy. The bleeding was observed during endoscopy for a period of time to determine if it would stop spontaneously. Moreover, the durability of ABS hemostasis was defined upon the results of endoscopic observation during the procedure, subsequent clinical and laboratory follow-up, and control endoscopy [<xref ref-type="table" rid="T0002">Table 2</xref>]. It is worth mentioning that we observed resolution of tachycardia during endoscopy upon ABS application in cases 2 and 3. The clinical rebleeding was assesed during hospitalization and after the procedure [<xref ref-type="table" rid="T0002">Table 2</xref>]. So, the bleeding severity of our cases at presentation and the durability of the treatment which was 3 to 7 days for three cases (cases 1 to 3) and approximately 12 hours for one case (case 4), ensure the ABS induced immediate and short term hemostasis. Despite our encouraging preliminary experience, the bleeding could have stopped spontaneously and not necessarily due to intervention with ABS. Thus, further studies including a large number of patients are needed to clarify its short term effect and long term durability. Moreover, technical details of ABS application for GI bleeding are not settled yet. The size of injured point and bleeding vessel, the general hemostatic status and the underlying illness should be the main determinants of success similar to other measures. Limited experience[<xref ref-type="bibr" rid="CIT6">6</xref>&#x2013;<xref ref-type="bibr" rid="CIT12">12</xref>] suggests, small doses of ABS stop bleeding from oozing lesions, within seconds. However, spurting lesions in our cases necessitated 7-25ml of ABS and bleeding stopped within a few minutes. We instilled ABS usually in a blind fashion due to severity of bleeding, but the exact localisation of bleeding point would lead to direct application of ABS onto the injured area with a smaller dose.</p>
      <p>The basic mechanism of action for ABS is the formation of an encapsulated protein network that provides focal attachment points for very rapid vital erythrocyte aggregation like an &#x201C;erythrocyte magnet&#x201D;, which is known as the hemostatic &#x201C;ABS-web&#x201D;. Macroscopically, it causes a brownish or greyish-yellow deposit at the bleeding areas [Figures <xref ref-type="fig" rid="F0001">1</xref> and <xref ref-type="fig" rid="F0002">2</xref>]. Recently, ultrastructural and morphological analysis of ABS induced coagulum was illustrated under the scanning electron microscopy.[<xref ref-type="bibr" rid="CIT9">9</xref>] ABS-induced protein network enriched with blood cells, particularly erythrocytes, covers the primary and secondary hemostatic system without disturbing individual coagulation factors or platelets.[<xref ref-type="bibr" rid="CIT3">3</xref><xref ref-type="bibr" rid="CIT9">9</xref>]</p>
      <p>In conclusion, we observed the hemostatic effect of ABS in variceal bleeding, prompting us to consider that it may be used as a bridge to rescue therapy in variceal bleeding. We could not fully define its further advantages or disadvantages from this small observational case series. In spite of our promising data, these findings are preliminary and need to be confirmed in further studies.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p><bold>Source of Support:</bold> Nil</p>
      </fn>
      <fn fn-type="conflict">
        <p><bold>Conflict of Interest:</bold> None declared.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="CIT1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia-Tsao</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sanyal</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Grace</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Carey</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis</article-title>
          <source>H epatology</source>
          <year>2007</year>
          <volume>46</volume>
          <fpage>922</fpage>
          <lpage>38</lpage>
        </element-citation>
      </ref>
      <ref id="CIT2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hou</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>FY</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
          <article-title>A randomized trial of endoscopic cyanoacrylate injection for acute gastric variceal bleeding: 0.5 mL versus 1.0 mL</article-title>
          <source>Gastrointest Endosc</source>
          <year>2009</year>
          <volume>70</volume>
          <fpage>668</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="pmid">19559427</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goker</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Haznedaroglu</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Ercetin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kirazli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Akman</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Ozturk</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Haemostatic actions of the folkloric medicinal plant extract, Ankaferd blood stopper</article-title>
          <source>J Int Med Res</source>
          <year>2008</year>
          <volume>36</volume>
          <fpage>163</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="pmid">18304416</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kosar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cipil</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Kaya</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Uz</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Haznedaroglu</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Goker</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model</article-title>
          <source>Blood Coagul Fibrinolysis</source>
          <year>2009</year>
          <volume>20</volume>
          <fpage>185</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="pmid">19657315</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bilgili</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kosar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kurt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Onal</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Goker</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Captug</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hemostatic efficacy of Ankaferd Blood Stopper in a swine bleeding model</article-title>
          <source>Med Princ Pract</source>
          <year>2009</year>
          <volume>18</volume>
          <fpage>165</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">19349716</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Teker</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Korkut</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Gedikli</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Kahya</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Prospective, controlled clinical trial of Ankaferd Blood Stopper in children undergoing tonsillectomy</article-title>
          <source>Int J Pediatr Otorhinolaryngol</source>
          <year>2009</year>
          <volume>73</volume>
          <fpage>1742</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">19836089</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kurt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kacar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Onal</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Akdogan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Haznedaroglu</surname>
              <given-names>IC</given-names>
            </name>
          </person-group>
          <article-title>Ankaferd Blood Stoper as an effective adjunctive hemostatic agent for the management of life-threatening arterial bleeding of the digestive tract</article-title>
          <source>Endoscopy</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>E262</fpage>
          <pub-id pub-id-type="pmid">19090459</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kurt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Akdogan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Onal</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Kekilli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Arhan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shorbagi</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Endoscopic topical application of Ankaferd Blood Stopper for neoplastic gastrointestinal bleeding: A retrospective analysis</article-title>
          <source>Dig Liver Dis 2009</source>
          <year>2010</year>
          <volume>42</volume>
          <fpage>196</fpage>
          <lpage>9</lpage>
        </element-citation>
      </ref>
      <ref id="CIT9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haznedaroglu</surname>
              <given-names>BZ</given-names>
            </name>
            <name>
              <surname>Haznedaroglu</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Bilgili</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Goker</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kosar</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ultrastructural and morphological analyses of the in vitro and in vivo hemostatic effects of ankaferd blood stopper</article-title>
          <source>Clin Appl Thromb Hemost</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>446</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="pmid">19833624</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bilgili</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Captug</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Kosar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kurt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kekilli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shorbagi</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oral systemic administration of Ankaferd Blood Stopper has no short-term toxicity in an <italic>in vivo</italic> rabbit experimental model</article-title>
          <source>Clin Appl Thromb Hemost</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>533</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">19605378</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kurt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Disibeyaz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Akdogan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sasmaz</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Aksu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Haznedaroglu</surname>
              <given-names>IC</given-names>
            </name>
          </person-group>
          <article-title>Endoscopic application of ankaferd blood stopper as a novel experimental treatment modality for upper gastrointestinal bleeding: A case report</article-title>
          <source>Am J Gastroenterol</source>
          <year>2008</year>
          <volume>103</volume>
          <fpage>2156</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">18796123</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tuncer</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Doganay</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ozturk</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Instant control of fundal variceal bleeding with a folkloric medicinal plant extract: Ankaferd Blood Stopper</article-title>
          <source>Gastrointest Endosc</source>
          <year>2010</year>
          <volume>71</volume>
          <fpage>873</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">19922917</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
